What the FDA labels say about taking them together
Itraconazole and mometasone
Mometasone's FDA label of August 19, 2026 names itraconazole in its drug interactions (prescription label) section; the itraconazole labels PlainMeds reads (2) do not name mometasone. The mometasone label: “Interactions with Strong Cytochrome P450 3A4 Inhibitors Caution should be exercised when considering the coadministration of ASMANEX HFA with ketoconazole, and other known strong cytochrome P450 (CYP) isoenzyme 3A4 …”
Check it at the source: the itraconazole FDA label on DailyMed (effective July 13, 2026, Janssen Pharmaceuticals, Inc.); the mometasone FDA label on DailyMed (effective August 19, 2026, L. Perrigo Company).
What does the itraconazole label say about mometasone?
Itraconazole's label (effective July 13, 2026) and its 1 other brand-application label do not name mometasone in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (SPORANOX), Janssen Pharmaceuticals, Inc., effective July 13, 2026 (SPL set a4d555fa-787c-40fb-bb7d-b0d4f7318fd0), via openFDA; the full label on DailyMed
What does the mometasone label say about itraconazole?
Mometasone label, drug interactions (prescription label)Caution should be exercised when considering the coadministration of mometasone furoate monohydrate nasal spray with long-term ketoconazole and other known strong CYP3A4 inhibitors (e.g., ritonavir, cobicistat-containing products, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, telithromycin) [see Clinical Pharmacology (12.3) ].
Asmanex Hfa label (Organon LLC, July 7, 2026), warnings and precautionsInteractions with Strong Cytochrome P450 3A4 Inhibitors Caution should be exercised when considering the coadministration of ASMANEX HFA with ketoconazole, and other known strong cytochrome P450 (CYP) isoenzyme 3A4 (CYP3A4) inhibitors (e.g., ritonavir, cobicistat-containing products, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, telithromycin) because adverse effects related to increased systemic exposure to mometasone furoate may occur [see Drug Interactions (7.1) and Clinical Pharmacology (12.3) ].
Source: FDA drug label (Asmanex Hfa, NDA205641), Organon LLC, effective July 7, 2026 (SPL set 0c6d63da-41bc-4894-bead-198e66c848ac), via openFDA
Source: FDA drug label (Asmanex, NDA021067), Organon LLC, effective July 7, 2026 (SPL set 10b36fb2-6b0d-4f20-b197-3564d6f594b9), via openFDA
Source: FDA drug label (Nasonex), L. Perrigo Company, effective August 19, 2026 (SPL set 13696a8b-366a-4a5e-adea-d5b7bff9e46f), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Itraconazole | Mometasone | |
|---|---|---|
| Labeled for | Fungal infections | Allergies, Asthma |
| Boxed warning | Yes | No |
| Pharmacy cost (NADAC) | $0.910 per capsule 100 mg capsule | $0.354 per gram 0.1% cream |
| Shortage now | A presentation being discontinued | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once